Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes

BACKGROUND: Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) case series. RESEARCH QUESTION: The goal of this study was to determine if tocilizumab benefits patients hospitalized with C...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Chest
المؤلفون الرئيسيون: Price, Christina C., Altice, Frederick L., Shyr, Yu, Koff, Alan, Pischel, Lauren, Goshua, George, Azar, Marwan M., Mcmanus, Dayna, Chen, Sheau-Chiann, Gleeson, Shana E., Britto, Clemente J., Azmy, Veronica, Kaman, Kelsey, Gaston, David C., Davis, Matthew, Burrello, Trisha, Harris, Zachary, Villanueva, Merceditas S., Aoun-Barakat, Lydia, Kang, Insoo, Seropian, Stuart, Chupp, Geoffrey, Bucala, Richard, Kaminski, Naftali, Lee, Alfred I., LoRusso, Patricia Mucci, Topal, Jeffrey E., Dela Cruz, Charles, Malinis, Maricar
التنسيق: Artigo
اللغة:Inglês
منشور في: American College of Chest Physicians 2020
الموضوعات:
Chest Infections: Original Research
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC7831876/
https://ncbi.nlm.nih.gov/pubmed/32553536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2020.06.006
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة